Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion of the conversation is that the user experienced noticeable regrowth of hair after using dutasteride as a single treatment for about 1.5 years. No before photos were available.

User has diffuse thinning crown and uses combover with hair spray. Oral minoxidil showed amazing results for another user.

A user using finasteride and dutasteride to treat hair loss, but still losing hair rapidly after stopping minoxidil. Replies suggest that the user should try oral minoxidil or switch to dutasteride for better results.

A user's 23 year experience with Finasteride/Dutasteride and their current consideration of adding Minoxidil to their treatments for hair loss.

Hair loss treatments, specifically the use of oral minoxidil in combination with micro-needling. Oral minoxidil has been found to improve hair density in 90% of patients with a low side effect profile, but using 5mg per day can result in higher side effects including hypertrichosis and edema. Other treatments mentioned include finasteride and RU58841.

A user is concerned about starting finasteride due to negative reports and potential side effects. Other users suggest talking to a doctor, considering personal tolerance, and note that side effects are rare.

Using both finasteride and dutasteride for hair loss is debated, with some seeing it as beneficial during transition, while others find it redundant and risky. Oral minoxidil raises concerns about blood pressure, with a preference for topical use and microneedling for better results.

User shared before and after photos of hair regrowth using Dutasteride 5x a week for 19 months. They experienced significant improvement and thanked others for their support.

Naepo's 5-month progress report detailing their journey of treating male pattern baldness with dutasteride and oral minoxidil, which has already resulted in an encouraging improvement in hair density. Others have responded with appreciation for the thorough report and asked further questions about Naepo's educational background.

The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.

The brain resists updating its perception of gradual appearance changes, like hair loss, due to its preference for stability and reliance on an internal model. This delay in perception can make changes feel sudden once the brain finally updates its model.

The conversation discusses whether individuals using hair loss treatments like Dutasteride (Dut) or Finasteride (Fin) should regularly check their hormone levels through bloodwork. Some argue it's important to monitor the effects of these medications on hormone levels, while others believe it's unnecessary if there are no side effects, citing cost and practicality concerns.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Finasteride treatment is being considered, and it's advised to track DHT, testosterone, estradiol, and SHBG levels to monitor hormonal changes. These tests will help understand the treatment's impact.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Stress can lead to hair loss by affecting hair-follicle stem cells, and this loss is harder to recover from if one has male pattern baldness (MPB). Treatments like finasteride and minoxidil are used to address hair loss, but stress-related hair loss differs from androgenic alopecia.

User discusses frustration with hair loss treatments and lack of progress. Emphasizes importance of measuring blood hormone levels to understand treatment effectiveness and side effects.

A user created a web app called TrichoMetrics to track hair loss using photos and metrics like density and thinning. The app supports tracking treatments like Minoxidil and finasteride, with features for setting baselines, comparing progress, and logging treatment adherence.

A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.

The user is considering changing their hair loss treatment from topical minoxidil and oral finasteride to oral minoxidil and oral dutasteride, with suggestions to add microneedling and possibly red light therapy. They are also exploring the addition of a caffeine and adenosine mix to their regimen.

A user is developing a tool to track hair density, aiming to help those using treatments like minoxidil. They seek feedback on the tool's usefulness and are considering a low-cost model to cover expenses.

The post discusses a holistic, bioenergetic approach to hair loss, focusing on diet, exercise, and lifestyle changes rather than traditional treatments like finasteride or minoxidil. Key dietary recommendations include fruits, milk, potatoes, butter, coconut oil, eggs, oysters, liver, and gelatin, along with moderate exercise and lifestyle adjustments to reduce stress.

The post discusses using ImageJ software to objectively track hair regrowth progress. The user is treating Androgen alopecia with dutasteride and minoxidil.

Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.

The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.

A user created a free AI-powered hair transplant simulator to help visualize post-transplant results, seeking feedback and offering it as a tool for clinics. Users discussed its usefulness, limitations, and the requirement for email and phone verification to prevent abuse.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.